Clinical and Genetic Analyzes of Age-related Macular Degeneration
NCT ID: NCT03614481
Last Updated: 2023-05-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
6000 participants
OBSERVATIONAL
2005-11-30
2024-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
AMD Phenotype and Genotype Study
NCT01778491
Ocular, Vascular, and Genetic Findings in AMD Patients
NCT06015633
Functional and Anatomical Visual Investigations in Patients With Early Forms of Age-related Macular Degeneration
NCT06694272
CNV in AMD Analyzed by OCT Angiography Under IntravitreaL Eylea (COCTAEyl)
NCT03803631
Comparison of Cytokine Profiles in Aqueous Humor of Patients With Age Related Macular Degeneration (AMD)
NCT03418220
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AMD patient
During the AMD consultation, patients have their imaging exams including OCT, retinophotography, and fluorescein angiography.
After the interview with the doctor on pathology diagnosis and follow-up, they will meet the clinical research associate nurse to complete the questionnaire and perform anthropometric measurements (weight, height, abdominal perimeter measurement and blood pressure measurement). Patients recruited at Créteil will benefit from a venous blood sample (20 mL) in 2 EDTA tubes for DNA extraction after light reading and signature of consent. For patients recruited from other ophthalmic centers, the Clinical Research Associate will perform salivary sampling for DNA extraction after light reading and signature of consent.
Sampling
Sampling
control without AMD
898/5000 Given the observation of a mutation in an unaffected control individual, it is not excluded that this individual may be suffering from AMD at a later age. The observation of the mutation could thus be considered as a pre-clinical test. None of the teams were able to obtain a control population of the same age and sex ratio, which could have benefited from fluorescein angiography or at least a fundus examination, to ensure the absence of warning signs of AMD. This requires cooperation from healthy elderly volunteers not only for blood sampling but also for pupillary dilatation.
The controls may be the accompanying persons or spouses of AMD patients. It may also be people seen in general consultation without maculopathy or retinopathy with an age greater than 55 years.
Sampling
Sampling
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sampling
Sampling
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of exudative or atrophic AMD in at least one eye
* Patient informed of the objectives of the study and having freely signed the informed consent letter
* Patient affiliated to a social security scheme
Exclusion Criteria
* History of severe systemic disease that could potentially hinder patient adherence to the study protocol: mental disorder, cancer, recent stroke or heart failure less than 3 months old.
* Known allergy to fluorescein, indocyanine green, iodine or ranibizumab
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Intercommunal Creteil
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Pellegrin
Bordeaux, , France
CHI Créteil
Créteil, , France
Hôpital général de Dijon
Dijon, , France
Hôpital des Quinze-Vingts
Paris, , France
Centre ophtalmologique d'imagerie et de laser
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Eric Soueid
Role: primary
Cohen
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2013-A00110-45
Identifier Type: OTHER
Identifier Source: secondary_id
COLLECTION DMLA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.